Drugs / mFOLFIRINOX
mFOLFIRINOX
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04835064 | Apr 2021 → Apr 2024 | pancreatic adenocarcinoma | Fudan University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06360354 Background | May 2024 → Oct 2026 expected | digestive system carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06179160 Background | Jan 2024 → Jan 2027 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07522073 Background | Apr 2026 → Sep 2028 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mFOLFIRINOX | “mFOLFIRINOX” NCT07522073 ↗ |
| Known as | calcium leucofolate | “calcium leucofolate \[LV\]” NCT04835064 ↗ |
| Known as | Modified FOLFIRINOX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06360354 ↗ |
| Route | Intravenous | “LV 400 mg/m2 intravenous infusion for 2 h, Day 1” NCT04835064 ↗ |